Investor Presentaiton

Investor presentation Full year 2018 Slide 75 The GLP-1 segment accounts for 17% of total diabetes care market value in North America DKK billion 53 70 60 50- 40- 30 20- 10 0 Nov 2013 North America GLP-1 market Key points on VictozaⓇ and Ozempic® in the USA VictozaⓇ and OzempicⓇ value market share within the GLP-1 segment is 45%2 Around 93% of new patients who start on VictozaⓇ transition from outside of the GLP-1 segment. Around 72% of new patients who start on OzempicⓇ transition from outside of GLP-1 segment³ Unrestricted access for OzempicⓇ for commercial and Medicare Part D combined around 80% Around 71% of VictozaⓇ prescriptions are for the higher dose 1.8 mg. Around 38% of OzempicⓇ prescriptions are for the higher dose 1 mg4 VictozaⓇ Dulaglutide Exenatide -OzempicⓇ Other Share of total diabetes care • market GLP-1 market value 14% CAGR value¹: 39.0% 12% 10% 8% 6% 4% 2% 0% Nov 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Nov, 2018 value figures changing diabetes 2 Source: IQVIA NSP monthly, MAT Nov, 2018 3 IQVIA SOB, week 21 Dec 2018 (based on 4 week average) 4 IQVIA, NPA weekly, 28 Dec 2018 (based on 4 week average) novo nordisk

View entire presentation